BCX4430 freebase

Research use only, not for human use.

A viral RNA-dependent RNA polymerase (RdRp) inhibitor that acts as a non-obligate RNA chain terminator.

A viral RNA-dependent RNA polymerase (RdRp) inhibitor that acts as a non-obligate RNA chain terminator; exhibits broad-spectrum antiviral activity against negative-sense RNA viruses representing the Filoviridae, Arenaviridae, Bunyaviridae,Orthomyxoviridae,Picornaviridae and Paramyxoviridae families, and positive-sense RNA viruses of the Flaviviridae and Coronaviridae families (EC50=5-60 uM).Ebola Virus Infection Phase 1 Clinical.

Cellular kinases phosphorylate Galidesivir (BCX4430) to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination.Galidesivir effectively inhibits the infection of Vero cells with YFV. The EC50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM).

Galidesivir (BCX4430) is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy.Galidesivir (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF). Animal Model:Female Syrian golden hamsters (hamsters infected with YF virus)Dosage:4 mg/kg of body weight Administration:I.p.; twice daily for 7 days Result:Significantly improved the survival of hamsters infected with YFV.

Galidesivir

Microbiology/Virology

Filovirus

Filovirus

Infection

Ebola Virus Infection

249503-25-1

265.2685

C11H15N5O3

>98% (HPLC)

H2O: 1.53 mg/mL (Need ultrasonic and warming)

C1=C(C2=C(N1)C(=NC=N2)N)C3C(C(C(N3)CO)O)O

3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-, (2S,3S,4R,5R)-

(-20℃)

With Ice Pack

≥ 2 years